Medicine
AAV9 news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
News cycle
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
Neurogene says 10 Rett syndrome participants treated with NGN-401 gained developmental milestones through up to 30 months of follow-up.
Why now
Rett stories are emotionally powerful because development can regress after early childhood milestones.
CIRM awarded $4.9 million to advance FRF-001, an AAV9 gene therapy for FOXG1 syndrome, through a Phase 1/2 clinical trial.
Why now
Parent-led foundations are increasingly becoming drug-development engines for devastating rare pediatric disorders.
Riaan Singh Digeorge received an experimental AAV9 gene therapy after a parent-led rare-disease development effort raised millions and reached an FDA-cleared IND.
Why now
A parent-led effort moved an ultra-rare disease from no approved treatment to first-in-human dosing, making the development story as important as the science.
Research map
Research records connected to this topic through topic tags, source records, and timeline events.
No directly linked studies are available for this page yet. Topic-only matches are not shown as evidence.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
